首页 > 最新文献

Medical Journal of Australia最新文献

英文 中文
Towards evidence-based skin checks 实现循证皮肤检查。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-06 DOI: 10.5694/mja2.52443
Linda K Martin, Pascale Guitera, Georgina V Long, Richard A Scolyer, Anne E Cust
<p>Melanoma is often referred to as Australia's national cancer, with the highest incidence per capita in the world due to the combination of high solar ultraviolet radiation levels, a temperate climate, outdoor lifestyle and genetically susceptible population.<span><sup>1</sup></span> Melanoma is our third most common invasive cancer, and two-thirds of Australians will be diagnosed with keratinocytic tumours (including basal cell and squamous cell carcinomas).<span><sup>2</sup></span> Despite advances in treatment and improved survival over the past decade, one Australian dies about every six hours from melanoma.<span><sup>3</sup></span></p><p>Routine skin checks occur widely in Australia, with about one-third of Australian adults aged 45–69 years reporting having a whole-body skin check annually.<span><sup>4</sup></span> This form of ad-hoc screening is contrary to national and international recommendations, with both the Australian Government Standing Committee on Screening<span><sup>5</sup></span> and United States Preventive Services Taskforce<span><sup>6</sup></span> concluding insufficient information on the benefits and harms of skin cancer screening, and lack of data on cost-effectiveness. Herein, we discuss the need for evidence-based approaches to skin cancer detection in Australia. Risk factors and diagnostic techniques for melanoma and keratinocyte carcinoma overlap. This perspective article focuses on melanoma, which is most likely to be associated with mortality, and its detection and cost benefits from an organised screening program.</p><p>“Population screening” refers to an organised program to identify disease in asymptomatic populations.<span><sup>5</sup></span> Australian clinical practice guidelines recommend “opportunistic screening”, that is, patient-driven or clinician-initiated skin checks occurring outside an organised program, for patients at increased risk of melanoma, and six- to 12-monthly skin checks for anyone who has ever had a melanoma (targeted screening).<span><sup>7</sup></span> Detection and treatment of melanoma at an early stage is associated with an excellent prognosis, and increased mortality has been demonstrated with each 0.2 mm increment in Breslow thickness at diagnosis.<span><sup>8</sup></span></p><p>Skin cancer is Australia's most expensive cancer, with direct costs to the health care system of almost $2 billion per year.<span><sup>9</sup></span> The additional cost of skin checks that do not result in a diagnosis of skin cancer is difficult to accurately quantify, as there is no Medicare item or process to collect these data. Current reimbursement models reward high patient volume and high biopsy rates, and community fear of cancer and clinician fear of error can also drive over-servicing. The potential non-financial costs of skin checks include patient anxiety, overdiagnosis and surgical burden.<span><sup>10</sup></span> Increasing government spending on skin checks and skin cancer treatments may
15 考虑本视角文章中概述的挑战将有助于我们实现这一目标。作为 Wiley - 新南威尔士大学协议的一部分,新南威尔士大学通过澳大利亚大学图书馆员理事会为开放存取出版提供了便利。Georgina Long 是 Agenus、AMGEN、Array Biopharma、AstraZeneca、Boehringer Ingelheim、Bristol-Myers Squibb、Evaxion、Hexal(Sandoz Company)、Highlight Therapeutics、Innovent Biologics USA、Merck Sharpe &amp; Dohme、Novartis、OncoSec、PHMR、Pierre-Fabre、Provectus Biopharmaceuticals Australia、Qbiotics 和 Regeneron 的顾问。Richard Scolyer 从霍夫曼-罗氏有限公司、Evaxion、Provectus 生物制药澳大利亚公司、Qbiotics、诺华、默克夏普、NeraCare、AMGEN、百时美施贵宝、Myriad Genetics 和葛兰素史克获得专业服务费。Pascale Guitera 是 MetaOptima 的顾问。
{"title":"Towards evidence-based skin checks","authors":"Linda K Martin,&nbsp;Pascale Guitera,&nbsp;Georgina V Long,&nbsp;Richard A Scolyer,&nbsp;Anne E Cust","doi":"10.5694/mja2.52443","DOIUrl":"10.5694/mja2.52443","url":null,"abstract":"&lt;p&gt;Melanoma is often referred to as Australia's national cancer, with the highest incidence per capita in the world due to the combination of high solar ultraviolet radiation levels, a temperate climate, outdoor lifestyle and genetically susceptible population.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Melanoma is our third most common invasive cancer, and two-thirds of Australians will be diagnosed with keratinocytic tumours (including basal cell and squamous cell carcinomas).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Despite advances in treatment and improved survival over the past decade, one Australian dies about every six hours from melanoma.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Routine skin checks occur widely in Australia, with about one-third of Australian adults aged 45–69 years reporting having a whole-body skin check annually.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; This form of ad-hoc screening is contrary to national and international recommendations, with both the Australian Government Standing Committee on Screening&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; and United States Preventive Services Taskforce&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; concluding insufficient information on the benefits and harms of skin cancer screening, and lack of data on cost-effectiveness. Herein, we discuss the need for evidence-based approaches to skin cancer detection in Australia. Risk factors and diagnostic techniques for melanoma and keratinocyte carcinoma overlap. This perspective article focuses on melanoma, which is most likely to be associated with mortality, and its detection and cost benefits from an organised screening program.&lt;/p&gt;&lt;p&gt;“Population screening” refers to an organised program to identify disease in asymptomatic populations.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Australian clinical practice guidelines recommend “opportunistic screening”, that is, patient-driven or clinician-initiated skin checks occurring outside an organised program, for patients at increased risk of melanoma, and six- to 12-monthly skin checks for anyone who has ever had a melanoma (targeted screening).&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; Detection and treatment of melanoma at an early stage is associated with an excellent prognosis, and increased mortality has been demonstrated with each 0.2 mm increment in Breslow thickness at diagnosis.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Skin cancer is Australia's most expensive cancer, with direct costs to the health care system of almost $2 billion per year.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; The additional cost of skin checks that do not result in a diagnosis of skin cancer is difficult to accurately quantify, as there is no Medicare item or process to collect these data. Current reimbursement models reward high patient volume and high biopsy rates, and community fear of cancer and clinician fear of error can also drive over-servicing. The potential non-financial costs of skin checks include patient anxiety, overdiagnosis and surgical burden.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; Increasing government spending on skin checks and skin cancer treatments may ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 8","pages":"407-409"},"PeriodicalIF":6.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52443","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood 在澳大利亚红十字会生命之血对献血者进行常规铁蛋白检测的时代,更新铁缺乏症的诊断和管理。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-03 DOI: 10.5694/mja2.52429
Gary D Zhang, Daniel Johnstone, Michael F Leahy, John K Olynyk
<p>Iron deficiency is the most common micronutrient deficiency worldwide<span><sup>1</sup></span> and the predominant cause of anaemia, which affects one-quarter of the global population.<span><sup>2</sup></span></p><p>In Australia, 22.3% of women have depleted iron stores (serum ferritin level < 30 μg/L), with pre-menopausal women disproportionately affected.<span><sup>3</sup></span> In contrast, 3.5% of men are iron deficient.<span><sup>3</sup></span></p><p>The Australian Red Cross Lifeblood implemented routine ferritin level testing in August 2023 for new whole blood donors (105 069 in 2023),<span><sup>4</sup></span> with expanded testing to include returning blood donors in 2024.<span><sup>5</sup></span> Donors are formally advised if their ferritin result is outside the reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.<span><sup>5</sup></span> This will identify a considerable number of iron deficient adults who will be directed to their primary care physician for management. In the context of this policy change and implications for primary care, this article provides a guide for investigating and managing absolute iron deficiency.</p><p>Iron stores inadequate to meet the demands of the body result in absolute iron deficiency, which is associated with a compensatory reduction in serum hepcidin concentration to stimulate an increase in gastrointestinal iron absorption and restore homeostasis.<span><sup>6-8</sup></span> Functional iron deficiency occurs when relatively normal iron stores are unable to be released for physiological requirements due to inappropriately elevated serum hepcidin levels, as may occur in chronic inflammatory conditions, including obesity, chronic disease and neoplasia.<span><sup>6-8</sup></span> Absolute and functional iron deficiency can also co-exist.<span><sup>7</sup></span> A ferritin level below the reference interval should always be interpreted as absolute iron deficiency.</p><p>The diagnosis of iron deficiency is based on routinely available blood biomarkers as described in Box 1. Serum ferritin level cut-offs to diagnose iron deficiency vary considerably,<span><sup>9</sup></span> from less than 15 μg/L used by the World Health Organization,<span><sup>10</sup></span> which predicts absent iron stores with very high specificity,<span><sup>7</sup></span> to less than 30 μg/L commonly used in Australia.<span><sup>7, 8, 11, 12</sup></span> Although the sex-based cut-offs adopted by the Australian Red Cross Lifeblood were reportedly derived from the Royal College of Pathologists of Australasia,<span><sup>12</sup></span> there is significant concern regarding inequalities using unconventional sex-based cut-offs, with underdiagnosis and undertreatment of iron deficient women. As an acute-phase reactant, ferritin may be falsely normal or elevated in iron deficient individuals when there is concurrent inflammation, obesity, steatotic liver disease, malignancy or other chronic dise
开始铁剂治疗后,应在 2 到 4 周内检查血红蛋白水平,预计血红蛋白水平会上升 10 克/升以上。6 在最初的三个月中,应每月测量血清铁蛋白和血红蛋白水平,目标是血清铁蛋白恢复正常或 IDA 患者的血红蛋白上升 20 克/升。6 在出现有效反应后,应继续口服铁剂至少三个月;如果反应不充分,则应考虑是否存在依从性和铁吸收障碍。此后,在治疗缺铁症及其根本原因后的 12 个月内,应每隔三到六个月监测一次铁蛋白和血红蛋白水平。6 如果铁蛋白和血红蛋白水平不能保持稳定,则应重新开始补充铁剂,并考虑进行进一步检查。澳大利亚红十字会生命之血实施的常规铁蛋白检测将提高对献血者缺铁症的检测率。血清铁蛋白水平低可诊断为绝对缺铁,需要进行临床评估。缺铁的病因可大致分为生理性、饮食摄入或吸收不足、失血和罕见的遗传原因。应考虑对个人进行风险分层,以便有针对性地进行检查。确诊缺铁症后,应尽早开始补铁。
{"title":"Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood","authors":"Gary D Zhang,&nbsp;Daniel Johnstone,&nbsp;Michael F Leahy,&nbsp;John K Olynyk","doi":"10.5694/mja2.52429","DOIUrl":"10.5694/mja2.52429","url":null,"abstract":"&lt;p&gt;Iron deficiency is the most common micronutrient deficiency worldwide&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; and the predominant cause of anaemia, which affects one-quarter of the global population.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In Australia, 22.3% of women have depleted iron stores (serum ferritin level &lt; 30 μg/L), with pre-menopausal women disproportionately affected.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; In contrast, 3.5% of men are iron deficient.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The Australian Red Cross Lifeblood implemented routine ferritin level testing in August 2023 for new whole blood donors (105 069 in 2023),&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; with expanded testing to include returning blood donors in 2024.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Donors are formally advised if their ferritin result is outside the reference intervals of 15–400 μg/L for female donors and 30–500 μg/L for male donors.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; This will identify a considerable number of iron deficient adults who will be directed to their primary care physician for management. In the context of this policy change and implications for primary care, this article provides a guide for investigating and managing absolute iron deficiency.&lt;/p&gt;&lt;p&gt;Iron stores inadequate to meet the demands of the body result in absolute iron deficiency, which is associated with a compensatory reduction in serum hepcidin concentration to stimulate an increase in gastrointestinal iron absorption and restore homeostasis.&lt;span&gt;&lt;sup&gt;6-8&lt;/sup&gt;&lt;/span&gt; Functional iron deficiency occurs when relatively normal iron stores are unable to be released for physiological requirements due to inappropriately elevated serum hepcidin levels, as may occur in chronic inflammatory conditions, including obesity, chronic disease and neoplasia.&lt;span&gt;&lt;sup&gt;6-8&lt;/sup&gt;&lt;/span&gt; Absolute and functional iron deficiency can also co-exist.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; A ferritin level below the reference interval should always be interpreted as absolute iron deficiency.&lt;/p&gt;&lt;p&gt;The diagnosis of iron deficiency is based on routinely available blood biomarkers as described in Box 1. Serum ferritin level cut-offs to diagnose iron deficiency vary considerably,&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; from less than 15 μg/L used by the World Health Organization,&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; which predicts absent iron stores with very high specificity,&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; to less than 30 μg/L commonly used in Australia.&lt;span&gt;&lt;sup&gt;7, 8, 11, 12&lt;/sup&gt;&lt;/span&gt; Although the sex-based cut-offs adopted by the Australian Red Cross Lifeblood were reportedly derived from the Royal College of Pathologists of Australasia,&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt; there is significant concern regarding inequalities using unconventional sex-based cut-offs, with underdiagnosis and undertreatment of iron deficient women. As an acute-phase reactant, ferritin may be falsely normal or elevated in iron deficient individuals when there is concurrent inflammation, obesity, steatotic liver disease, malignancy or other chronic dise","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 7","pages":"360-364"},"PeriodicalIF":6.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context 澳大利亚药物使用的成本障碍:患者体验调查背景分析。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-03 DOI: 10.5694/mja2.52427
Narcyz Ghinea
<p>In November 2023, the Australian Bureau of Statistics (ABS) released its 2022–23 Patient Experience Survey data.<span><sup>1</sup></span> This latest release shows that many Australians struggle to afford the medicines they need and that cost barriers to access have increased compared with the previous year.</p><p>Women, younger people and those in poorer health are particularly affected. The data show that 9.4% of women compared with 5.5% of men reported cost-related non-adherence to medications (medication-CRNA) (ie, delaying or not filling scripts due to cost) prescribed by their general practitioner in the previous 12 months.<span><sup>2</sup></span> The proportion increases for younger women to 14.7% for 15–24-year-olds and to 13% for 25–34-year-olds (Box 1). However, considering that 8.4% of women (and as high as 11.3% for women aged 25–34 years) at least once delayed seeing or did not see a general practitioner,<span><sup>2</sup></span> and 12.2% (and as high as 20.3% for 25–34-year-olds) at least once delayed or did not see a specialist due to cost,<span><sup>3</sup></span> the proportion of women directly or indirectly affected by medication-CRNA would be even higher.</p><p>Younger Australians are more likely to experience cost barriers to care than older Australians. A 25–34-year-old is 2.7 times more likely to experience medication-CRNA than a 75–84-year-old, 3.1 times more likely to delay visiting or not visit a general practitioner due to cost,<span><sup>2</sup></span> and 3.8 times more likely to delay visiting or not visit a specialist due to cost.<span><sup>3</sup></span> For women, the discrepancy is much more pronounced, with 25–34-year-olds 3.5 times more likely to experience medication-CRNA than 75–84-year-olds, 3.8 times more likely to delay visiting or not visit a general practitioner, and 4.8 times more likely to delay visiting or not visit a specialist due to cost.</p><p>Health status also plays an important part, with 15% of individuals in fair or poor health experiencing medication-CRNA (2.3 times higher than those in good health) and 11.8% delay visiting or not visit a general practitioner due to cost (1.8 times higher).<span><sup>4</sup></span> For specialist visits the discrepancy was not as stark.<span><sup>5</sup></span> The most socio-economically disadvantaged people were also almost twice as likely to delay or not seek treatment than the most advantaged (Box 2).<span><sup>4</sup></span></p><p>The <i>de facto</i> rate of medication-CRNA is necessarily higher than what is reported in the ABS's survey. Their data are collected in the context of general practice visits only, so they would not include medicines prescribed by specialists. This is a significant lacuna since 42.2% of those surveyed needed to see a specialist,<span><sup>6</sup></span> and it is reasonable to assume many of these patients would be prescribed some medication. The Australians that miss out on seeing a general practitioner or specialist du
2023 年 11 月,澳大利亚统计局(ABS)发布了 2022-23 年度患者体验调查数据。1 最新发布的数据显示,许多澳大利亚人难以负担所需的药物,与上一年相比,获得药物的成本障碍有所增加。数据显示,9.4% 的女性(5.5% 的男性)报告在过去 12 个月内曾因费用问题而不遵医嘱用药(medication-CRNA)(即因费用问题而延迟或不开药)。然而,考虑到有 8.4%的妇女(25-34 岁的妇女高达 11.3%)至少有一次推迟看或不看全科医师,2 以及 12.2%的妇女(25-34 岁的妇女高达 20.3%)至少有一次因费用问题推迟看或不看专科医生,3 受药物治疗-CRNA 直接或间接影响的妇女比例会更高。25-34 岁年龄段的人比 75-84 岁年龄段的人更有可能遇到用药-CRNA 问题,因费用问题而推迟看或不看全科医生的可能性是 75-84 岁年龄段的人的 2.7 倍,2 因费用问题而推迟看或不看专科医生的可能性是 75-84 岁年龄段的人的 3.1 倍。对于女性来说,这种差异要明显得多,25-34 岁的女性比 75-84 岁的女性更有可能患上药物-CRNA,是 75-84 岁女性的 3.5 倍,更有可能推迟看或不看全科医生,是 75-84 岁女性的 3.8 倍,更有可能因为费用问题推迟看或不看专科医生,是 75-84 岁女性的 4.8 倍。健康状况也是一个重要因素,健康状况一般或较差的人中有 15%的人经历过用药-CRNA(比健康状况好的人高 2.3 倍),11.8%的人因费用原因推迟看或不看全科医生(高 1.8 倍)。社会经济条件最差的人群推迟就医或不就医的几率几乎是最富裕人群的两倍(插文 2)。他们的数据仅在普通诊所就诊时收集,因此不包括专科医生开出的药物。这是一个重大的空白,因为 42.2% 的受访者需要看专科医生,6 而且我们有理由认为,这些患者中有很多人都会被开一些药。经验证据也支持这样一个事实,即在整个人口和所有就医情况中,经历过药物治疗-CRNA 的澳大利亚人的总体比例要高于澳大利亚统计局的数据显示。2023 年公布的一项调查发现,在澳大利亚生活的 45 岁或以上、目前正在服用处方药的人中,有 21.9% 的人在过去 12 个月中的某个时间点曾经历过药物治疗--CRNA。7 这一结果在同一时期对 11000 人进行的另一项独立调查中也得到了完全相同的验证,尽管这次调查的样本并不局限于特定的年龄组。相比之下,澳大利亚统计局(ABS)的《患者体验调查》(Patient Experience Survey)报告称,45 岁及以上患者的药物滥用率高达 7.4%(45-54 岁),低至 4.3%(65-74 岁)。澳大利亚统计局的调查没有收集到一些重要的数据,而了解这些数据是至关重要的。那些只能通过牺牲预算来支付药物费用,从而严重影响其生活方式的患者的经历没有被记录下来。上述针对 45 岁及以上澳大利亚人的研究发现,17.7% 的处方药服用者在过去 12 个月的某个时间点不得不采取以下一种或多种措施来购买药物:不吃饭、不付账单、借钱、变卖资产、贷款或抵押贷款。2019 年发表的一项研究估计,自费医疗支出每年导致数十万澳大利亚人陷入收入贫困,2014 年有 28.5 万人陷入贫困。尽管澳大利亚统计局(ABS)报告的用药-CRNA 比率相对较低,但仍有 30% 的澳大利亚人认为买不起药,这一事实也证明了这一点。8 为支持循证政策改革以改善药品获取,我们需要更多关于整个医疗服务领域(而不仅仅是全科服务)的用药-CRNA 数据。 我们还需要了解有多少人所处方的药品不受药品福利计划(PBS)的补贴,因为这给患者增加了额外的成本障碍。10 根据澳大利亚卫生与福利研究所(Australian Institute of Health and Welfare)的数据,非 "药品福利计划"(PBS)药品的支出是澳大利亚人自费支出中最大的一类,约占总支出的三分之一。尽管如此,根据我们对药品成本上升的了解,13 以及临床实践中标签外处方的高比例(通常不受 PBS 补贴),10 我们有理由认为,在出现相反的证据之前,大部分支出都用于处方药。事实上,美国治疗用品管理局(Therapeutic Goods Administration)新推出的 "药品再利用计划"(Medicines Repurposing Program)的目的之一,就是通过登记具有公共卫生价值的标示外药品用途,使其能够获得补贴,从而改善公平的治疗机会。此外,我们需要更谨慎地考虑如何使用有限的资源,因为在澳大利亚等高收入国家,50% 以上的药品支出仅用于治疗 2-3% 的患者。2021-2022 年,在政府支出最高的 50 种 PBS 药物中,有 25 种药物的补贴处方不到 6 万张,但政府却为此花费了 37 亿美元,占当年 PBS 支出总额(147 亿美元)的四分之一。16 最后,还有一些人在无形中遭受着用药成本的障碍:患者在与医生讨论成本问题后,医生会给他们开一些劣质药(例如,疗效不如新药但价格更贵的旧药),或者根本不给他们开药。由于没有脚本,有关这种以成本为动机的劣质治疗的书面数据从未被记录下来,但在最新药物价格不断上涨并刷新纪录的时代,这些数据却非常重要,因为患者越来越难以承受这些药物。
{"title":"Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context","authors":"Narcyz Ghinea","doi":"10.5694/mja2.52427","DOIUrl":"10.5694/mja2.52427","url":null,"abstract":"&lt;p&gt;In November 2023, the Australian Bureau of Statistics (ABS) released its 2022–23 Patient Experience Survey data.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This latest release shows that many Australians struggle to afford the medicines they need and that cost barriers to access have increased compared with the previous year.&lt;/p&gt;&lt;p&gt;Women, younger people and those in poorer health are particularly affected. The data show that 9.4% of women compared with 5.5% of men reported cost-related non-adherence to medications (medication-CRNA) (ie, delaying or not filling scripts due to cost) prescribed by their general practitioner in the previous 12 months.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The proportion increases for younger women to 14.7% for 15–24-year-olds and to 13% for 25–34-year-olds (Box 1). However, considering that 8.4% of women (and as high as 11.3% for women aged 25–34 years) at least once delayed seeing or did not see a general practitioner,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and 12.2% (and as high as 20.3% for 25–34-year-olds) at least once delayed or did not see a specialist due to cost,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; the proportion of women directly or indirectly affected by medication-CRNA would be even higher.&lt;/p&gt;&lt;p&gt;Younger Australians are more likely to experience cost barriers to care than older Australians. A 25–34-year-old is 2.7 times more likely to experience medication-CRNA than a 75–84-year-old, 3.1 times more likely to delay visiting or not visit a general practitioner due to cost,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; and 3.8 times more likely to delay visiting or not visit a specialist due to cost.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; For women, the discrepancy is much more pronounced, with 25–34-year-olds 3.5 times more likely to experience medication-CRNA than 75–84-year-olds, 3.8 times more likely to delay visiting or not visit a general practitioner, and 4.8 times more likely to delay visiting or not visit a specialist due to cost.&lt;/p&gt;&lt;p&gt;Health status also plays an important part, with 15% of individuals in fair or poor health experiencing medication-CRNA (2.3 times higher than those in good health) and 11.8% delay visiting or not visit a general practitioner due to cost (1.8 times higher).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; For specialist visits the discrepancy was not as stark.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; The most socio-economically disadvantaged people were also almost twice as likely to delay or not seek treatment than the most advantaged (Box 2).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The &lt;i&gt;de facto&lt;/i&gt; rate of medication-CRNA is necessarily higher than what is reported in the ABS's survey. Their data are collected in the context of general practice visits only, so they would not include medicines prescribed by specialists. This is a significant lacuna since 42.2% of those surveyed needed to see a specialist,&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; and it is reasonable to assume many of these patients would be prescribed some medication. The Australians that miss out on seeing a general practitioner or specialist du","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 8","pages":"414-416"},"PeriodicalIF":6.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective 2023 年多囊卵巢综合征评估与管理国际循证指南摘要:澳大利亚视角。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-02 DOI: 10.5694/mja2.52432
Helena J Teede, Aya Mousa, Chau T Tay, Michael F Costello, Leah Brennan, Robert J Norman, Alexia S Pena, Jacqueline A Boyle, Anju Joham, Lorna Berry, Lisa Moran
<div> <section> <h3> Introduction</h3> <p>The Australian-led <i>2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome</i> was based on best available evidence, clinical expertise and consumer preference. It followed best practice, involved extensive evidence synthesis and applied relevant frameworks across evidence quality, feasibility, acceptability, cost and implementation. Thirty-nine societies and organisations covering 71 countries were engaged. The evidence in the assessment and management of polycystic ovary syndrome (PCOS) has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report, 52 systematic reviews and analyses (approximately 6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points.</p> </section> <section> <h3> Main recommendations</h3> <div>Changes include: <ul> <li>refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone levels as an alternative to ultrasound in adults only, and differentiation of adolescent and adult criteria;</li> <li>strengthening the recognition of broad features of PCOS including metabolic effects, cardiovascular disease, dermatological symptoms, sleep apnoea, a high prevalence of psychological features and a high risk of adverse pregnancy outcomes;</li> <li>emphasising the poorly recognised, diverse burden of disease, the vital need for greater health professional education, evidence-based patient information, improved models of care, shared decision making and research efforts to improve patient experience;</li> <li>maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and</li> <li>emphasising evidence-based medical therapy and cheaper and safer fertility management.</li> </ul> </div> </section> <section> <h3> Changes in management as a result of this guideline</h3> <p>The 2023 guideline is approved by the National Health and Medical Research Council and provides clinicians and patients with clear advice on best practice in a common and neglected condition, based on the best available evidence, expert multidisciplinary input and consumer preferences. It provides vital, extensive patient and provider resources to enhance evidence-based care.</p>
导言:由澳大利亚牵头制定的《2023 多囊卵巢综合症评估与管理国际循证指南》以现有最佳证据、临床专业知识和消费者偏好为基础。该指南遵循最佳实践,进行了广泛的证据综合,并在证据质量、可行性、可接受性、成本和实施方面应用了相关框架。覆盖 71 个国家的 39 个学会和组织参与了这项工作。在过去五年中,多囊卵巢综合症(PCOS)评估和管理方面的证据总体上有所改善,但质量仍处于中下水平。技术证据报告、52 项系统回顾和分析(约 6000 页)支持 77 项循证建议和 54 项共识建议,以及 123 项实践要点:变化包括完善单个诊断标准,简化诊断算法,将抗缪勒氏管激素水平作为成人超声检查的替代方法,并区分青少年和成人标准;加强对 PCOS 广泛特征的认识,包括代谢影响、心血管疾病、皮肤病症状、睡眠呼吸暂停、高发的心理特征和不良妊娠结局的高风险;强调对疾病的认识不足、疾病负担多样化、亟需加强卫生专业人员教育、循证患者信息、改进护理模式、共同决策和研究工作,以改善患者体验;继续强调健康的生活方式、情感福祉和生活质量,认识并考虑体重耻辱感;强调循证医学治疗以及更便宜、更安全的生育管理。本指南带来的管理变化:2023 年指南由国家健康与医学研究委员会批准,根据现有最佳证据、多学科专家意见和消费者偏好,为临床医生和患者提供了有关这一常见且被忽视疾病的最佳实践的明确建议。该指南提供了大量重要的患者和医疗服务提供者资源,以加强循证护理。指南全文见 www.monash.edu/medicine/mchri/pcos/guideline。
{"title":"Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective","authors":"Helena J Teede,&nbsp;Aya Mousa,&nbsp;Chau T Tay,&nbsp;Michael F Costello,&nbsp;Leah Brennan,&nbsp;Robert J Norman,&nbsp;Alexia S Pena,&nbsp;Jacqueline A Boyle,&nbsp;Anju Joham,&nbsp;Lorna Berry,&nbsp;Lisa Moran","doi":"10.5694/mja2.52432","DOIUrl":"10.5694/mja2.52432","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The Australian-led &lt;i&gt;2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome&lt;/i&gt; was based on best available evidence, clinical expertise and consumer preference. It followed best practice, involved extensive evidence synthesis and applied relevant frameworks across evidence quality, feasibility, acceptability, cost and implementation. Thirty-nine societies and organisations covering 71 countries were engaged. The evidence in the assessment and management of polycystic ovary syndrome (PCOS) has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report, 52 systematic reviews and analyses (approximately 6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main recommendations&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;Changes include:\u0000\u0000 &lt;ul&gt;\u0000 \u0000 &lt;li&gt;refinement of individual diagnostic criteria, a simplified diagnostic algorithm and inclusion of anti-Müllerian hormone levels as an alternative to ultrasound in adults only, and differentiation of adolescent and adult criteria;&lt;/li&gt;\u0000 \u0000 &lt;li&gt;strengthening the recognition of broad features of PCOS including metabolic effects, cardiovascular disease, dermatological symptoms, sleep apnoea, a high prevalence of psychological features and a high risk of adverse pregnancy outcomes;&lt;/li&gt;\u0000 \u0000 &lt;li&gt;emphasising the poorly recognised, diverse burden of disease, the vital need for greater health professional education, evidence-based patient information, improved models of care, shared decision making and research efforts to improve patient experience;&lt;/li&gt;\u0000 \u0000 &lt;li&gt;maintained emphasis on healthy lifestyle, emotional wellbeing and quality of life, with awareness and consideration of weight stigma; and&lt;/li&gt;\u0000 \u0000 &lt;li&gt;emphasising evidence-based medical therapy and cheaper and safer fertility management.&lt;/li&gt;\u0000 &lt;/ul&gt;\u0000 &lt;/div&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Changes in management as a result of this guideline&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The 2023 guideline is approved by the National Health and Medical Research Council and provides clinicians and patients with clear advice on best practice in a common and neglected condition, based on the best available evidence, expert multidisciplinary input and consumer preferences. It provides vital, extensive patient and provider resources to enhance evidence-based care.&lt;/p&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 7","pages":"389-395"},"PeriodicalIF":6.7,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is behind the declining incidence of melanoma in younger Australians? 澳大利亚年轻人黑色素瘤发病率下降的原因是什么?
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-01 DOI: 10.5694/mja2.52411
Anne E Cust, Richard A Scolyer AO, Georgina V Long AO
<p>Australia is globally lauded for its leadership in preventing skin cancer, predominantly caused by ultraviolet radiation from the sun, and the impact of its national and state-based public education campaigns, including the iconic Slip! Slap! Slop! (Seek! Slide!) campaign<span><sup>1</sup></span> and others focused on changing attitudes to tanning and sun protection behaviours, particularly among children and young adults.<span><sup>2</sup></span> These campaigns are recognised as key factors in the gradual reduction in the incidence of melanoma in people under the age of 30 years in Australia over the past 25 years,<span><sup>1, 3</sup></span> whereas melanoma incidence continues to increase among older people in Australia and in all age groups in most other countries.<span><sup>3, 4</sup></span> In Australia, high sun exposure is a more costly risk factor than tobacco use with respect to health system expenditure on cancer treatment.<span><sup>5</sup></span> Government investment in skin cancer prevention, at a tiny fraction of the cost of skin cancer treatment, provides about three times return on investment, and is therefore considered excellent value for money.<span><sup>1</sup></span></p><p>It is important that high quality, robust evidence guides health policy decisions. One methodological concern regarding the impact of skin cancer prevention campaigns is whether the decline in melanoma incidence among young Australians might be explained by an increasing proportion of migrants at low risk of melanoma, primarily because of their skin pigmentation, which would lower the overall risk in a population otherwise at high risk of melanoma.<span><sup>6</sup></span></p><p>This question is carefully addressed in the study by Whiteman and colleagues<span><sup>7</sup></span> reported in this issue of the <i>MJA</i>. The authors used Australian census data on the reported ancestry of participants’ parents to classify people as being at high, moderate, or low risk of melanoma, and modelled invasive melanoma incidence trends for each of these ancestry groups during 2006–2021. Whiteman and his colleagues<span><sup>7</sup></span> found that the ancestry-based composition of the Australian population, and thus its melanoma risk profile, had indeed changed over time, with the proportion of people at high risk of melanoma (ie, people with two parents of European ancestry) falling from 85% in 2006 to 71% in 2021, with concomitant rises in the proportions for the moderate risk (from 5% to 10%) and low risk categories (from 10% to 19%). As more than 95% of diagnosed melanomas were in people in the high risk ancestry group, the changing population composition was indeed associated with a decline in melanoma incidence. However, it did not fully explain the falling melanoma incidence in younger age groups; when incidence patterns for the high risk ancestry group were examined separately to remove the confounding effect of population change, declines in incidenc
Hoffmann-La Roche、Evaxion、Provectus Biopharmaceuticals Australia、Qbiotics、Novartis、Merck Sharp &amp; Dohme、NeraCare、AMGEN、Bristol-Myers Squibb、Myriad Genetics 和 GlaxoSmithKline。Georgina Long AO 还是 Agenus、Amgen、Array Biopharma、AstraZeneca、Bayer、BioNTech、Boehringer Ingelheim、Bristol Myers Squibb、Evaxion、Hexal(Sandoz Company)、Highlight Therapeutics、IOBiotech、Immunocore、Innovent Biologics USA、Merck Sharpe &amp; Dohme、Novartis、PHMR、Pierre Fabre、Regeneron、Scancell 和 SkylineDX 的顾问。委托撰写;未经外部同行评审。
{"title":"What is behind the declining incidence of melanoma in younger Australians?","authors":"Anne E Cust,&nbsp;Richard A Scolyer AO,&nbsp;Georgina V Long AO","doi":"10.5694/mja2.52411","DOIUrl":"10.5694/mja2.52411","url":null,"abstract":"&lt;p&gt;Australia is globally lauded for its leadership in preventing skin cancer, predominantly caused by ultraviolet radiation from the sun, and the impact of its national and state-based public education campaigns, including the iconic Slip! Slap! Slop! (Seek! Slide!) campaign&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; and others focused on changing attitudes to tanning and sun protection behaviours, particularly among children and young adults.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; These campaigns are recognised as key factors in the gradual reduction in the incidence of melanoma in people under the age of 30 years in Australia over the past 25 years,&lt;span&gt;&lt;sup&gt;1, 3&lt;/sup&gt;&lt;/span&gt; whereas melanoma incidence continues to increase among older people in Australia and in all age groups in most other countries.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; In Australia, high sun exposure is a more costly risk factor than tobacco use with respect to health system expenditure on cancer treatment.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Government investment in skin cancer prevention, at a tiny fraction of the cost of skin cancer treatment, provides about three times return on investment, and is therefore considered excellent value for money.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;It is important that high quality, robust evidence guides health policy decisions. One methodological concern regarding the impact of skin cancer prevention campaigns is whether the decline in melanoma incidence among young Australians might be explained by an increasing proportion of migrants at low risk of melanoma, primarily because of their skin pigmentation, which would lower the overall risk in a population otherwise at high risk of melanoma.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;This question is carefully addressed in the study by Whiteman and colleagues&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; reported in this issue of the &lt;i&gt;MJA&lt;/i&gt;. The authors used Australian census data on the reported ancestry of participants’ parents to classify people as being at high, moderate, or low risk of melanoma, and modelled invasive melanoma incidence trends for each of these ancestry groups during 2006–2021. Whiteman and his colleagues&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; found that the ancestry-based composition of the Australian population, and thus its melanoma risk profile, had indeed changed over time, with the proportion of people at high risk of melanoma (ie, people with two parents of European ancestry) falling from 85% in 2006 to 71% in 2021, with concomitant rises in the proportions for the moderate risk (from 5% to 10%) and low risk categories (from 10% to 19%). As more than 95% of diagnosed melanomas were in people in the high risk ancestry group, the changing population composition was indeed associated with a decline in melanoma incidence. However, it did not fully explain the falling melanoma incidence in younger age groups; when incidence patterns for the high risk ancestry group were examined separately to remove the confounding effect of population change, declines in incidenc","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 5","pages":"246-247"},"PeriodicalIF":6.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52411","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Building and acting on the evidence for primary prevention of cancer 积累癌症初级预防的证据并采取行动。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-01 DOI: 10.5694/mja2.52418
Elizabeth Zuccala
<p>Slip, Slop, Slap (and later, Seek, Slide)! Many readers will be familiar with this iconic Australian public health slogan that was launched in the early 1980s and became a core message of the Cancer Council's SunSmart program (https://cancer.org.au/cancer-information/causes-and-prevention/sun-safety/campaigns-and-events/slip-slop-slap-seek-slide). Australia has one of the highest rates of skin cancer in the world and over the past several decades has become a global leader in primary prevention and early detection efforts, with a particular focus on the use of media and advocacy campaigns aimed at improving the uptake of sun protection approaches. But teasing out the specific effects of public health campaigns is notoriously difficult. In the case of skin cancer, a major challenge facing researchers is how to measure the impacts of prevention efforts on disease burden in the context of rapidly changing population demographics, in particular those driven by migration.</p><p>In their research article published today in the <i>MJA</i>, Whiteman and colleagues (https://doi.org/10.5694/mja2.52404) present findings of their modelling study that aimed to investigate the extent to which recent declines in melanoma incidence among young Australians might be explained by the increasing population proportion of migrants who are at low risk of melanoma owing to their ancestry. The study found that among people aged under 35 years, the incidence of melanoma is declining, including for people who have a high risk (European) ancestry. They conclude that “migration may have had an impact on the incidence of melanoma among younger Australians, but social changes may also have contributed to its decline”. Social and behavioural changes that might have contributed to reducing ultraviolet radiation exposure among young Australians could include improved uptake of protective measures such as using appropriate clothing, wearing sunscreen and seeking shade, as well as lifestyle trends that lead to people spending less time outdoors. Writing in a linked editorial, Cust and colleagues (https://doi.org/10.5694/mja2.52411) argue that despite these nuanced findings, “given that the incidence of melanoma and other skin cancers is highest in Australia, and that they are the most expensive cancers to treat, ongoing skin cancer prevention campaigns and other targeted initiatives will be essential for further reducing the burden of this highly preventable disease”.</p><p>Cancer prevention is covered again by a perspective (https://doi.org/10.5694/mja2.52395) on hepatocellular carcinoma (HCC) among First Nations Australians, who are 2.5 times more likely to develop HCC and 1.4 times more likely to die of HCC than non-Indigenous Australians. Although most chronic liver disease is preventable and/or treatable, it remains the main cause of HCC, with First Nations Australians more likely to have multiple cofactors driving liver injury. The two lead authors of this article, one Fir
52408)指出,目前跟踪土著婴儿出生体重的方法可能会掩盖土著婴儿与非土著婴儿之间在健康出生体重比例方面存在的不平等程度。根据对 2011 年至 2020 年昆士兰围产期数据的分析,作者建议,为了跟踪在缩小儿童健康差距方面取得的进展,健康出生体重比例应根据婴儿及其母亲的土著身份来定义,而不是仅根据婴儿的土著身份来定义。
{"title":"Building and acting on the evidence for primary prevention of cancer","authors":"Elizabeth Zuccala","doi":"10.5694/mja2.52418","DOIUrl":"10.5694/mja2.52418","url":null,"abstract":"&lt;p&gt;Slip, Slop, Slap (and later, Seek, Slide)! Many readers will be familiar with this iconic Australian public health slogan that was launched in the early 1980s and became a core message of the Cancer Council's SunSmart program (https://cancer.org.au/cancer-information/causes-and-prevention/sun-safety/campaigns-and-events/slip-slop-slap-seek-slide). Australia has one of the highest rates of skin cancer in the world and over the past several decades has become a global leader in primary prevention and early detection efforts, with a particular focus on the use of media and advocacy campaigns aimed at improving the uptake of sun protection approaches. But teasing out the specific effects of public health campaigns is notoriously difficult. In the case of skin cancer, a major challenge facing researchers is how to measure the impacts of prevention efforts on disease burden in the context of rapidly changing population demographics, in particular those driven by migration.&lt;/p&gt;&lt;p&gt;In their research article published today in the &lt;i&gt;MJA&lt;/i&gt;, Whiteman and colleagues (https://doi.org/10.5694/mja2.52404) present findings of their modelling study that aimed to investigate the extent to which recent declines in melanoma incidence among young Australians might be explained by the increasing population proportion of migrants who are at low risk of melanoma owing to their ancestry. The study found that among people aged under 35 years, the incidence of melanoma is declining, including for people who have a high risk (European) ancestry. They conclude that “migration may have had an impact on the incidence of melanoma among younger Australians, but social changes may also have contributed to its decline”. Social and behavioural changes that might have contributed to reducing ultraviolet radiation exposure among young Australians could include improved uptake of protective measures such as using appropriate clothing, wearing sunscreen and seeking shade, as well as lifestyle trends that lead to people spending less time outdoors. Writing in a linked editorial, Cust and colleagues (https://doi.org/10.5694/mja2.52411) argue that despite these nuanced findings, “given that the incidence of melanoma and other skin cancers is highest in Australia, and that they are the most expensive cancers to treat, ongoing skin cancer prevention campaigns and other targeted initiatives will be essential for further reducing the burden of this highly preventable disease”.&lt;/p&gt;&lt;p&gt;Cancer prevention is covered again by a perspective (https://doi.org/10.5694/mja2.52395) on hepatocellular carcinoma (HCC) among First Nations Australians, who are 2.5 times more likely to develop HCC and 1.4 times more likely to die of HCC than non-Indigenous Australians. Although most chronic liver disease is preventable and/or treatable, it remains the main cause of HCC, with First Nations Australians more likely to have multiple cofactors driving liver injury. The two lead authors of this article, one Fir","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 5","pages":"229"},"PeriodicalIF":6.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the incidence of melanoma in Australia, 2006–2021, by age group and ancestry: a modelling study 2006-2021 年澳大利亚黑色素瘤发病率的变化(按年龄组和血统分列):一项模型研究。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-01 DOI: 10.5694/mja2.52404
David C Whiteman, Rachel E Neale, Peter Baade, Catherine M Olsen, Nirmala Pandeya

Objectives

To estimate the incidence of melanoma in Australia among people with ancestries associated with low, moderate, or high risk of melanoma, by sex and 5-year age group; to establish whether age-specific incidence rates by ancestry risk group have changed over time.

Study design

Modelling study; United States (SEER database) melanoma incidence rates for representative ancestral populations and Australian census data (2006, 2011, 2016, 2021) used to estimate Australian melanoma incidence rates by ancestry-based risk.

Setting, participants

Australia, 2006–2021.

Main outcome measures

Age-specific invasive melanoma incidence rates, and average annual percentage change (AAPC) in age-specific melanoma rates, by ancestry-based risk group, sex, and 5-year age group.

Results

The proportion of people in Australia who reported high risk (European) ancestry declined from 85.3% in 2006 to 71.1% in 2021. The estimated age-standardised melanoma incidence rate was higher for people with high risk ancestry (2021: males, 82.2 [95% confidence interval {CI}, 80.5–83.8] cases per 100 000 population; females, 58.5 [95% CI, 57.0–59.9] cases per 100 000 population) than for all Australians (males, 67.8 [95% CI, 66.5–69.2] cases per 100 000 population; females, 45.4 [95% CI, 44.3–46.5] cases per 100 000 population). AAPCs were consistently positive for Australians aged 50 years or older, both overall and for people with high risk ancestry, but were statistically significant only for some age groups beyond 65 years. AAPCs were negative for people aged 34 years or younger, but were generally not statistically significant.

Conclusions

Melanoma incidence has declined in some younger age groups in Australia, including among people with high risk ancestry. Social and behavioural changes over the same period that lead to lower levels of ultraviolet radiation exposure probably contributed to these changes.

研究目的按性别和5岁年龄组估算澳大利亚黑色素瘤低、中、高风险血统人群的黑色素瘤发病率;确定按血统风险组划分的特定年龄发病率是否随时间推移而变化:模型研究;美国(SEER 数据库)代表性祖先人群的黑色素瘤发病率和澳大利亚人口普查数据(2006 年、2011 年、2016 年、2021 年)用于按祖先风险估算澳大利亚黑色素瘤发病率:主要结果指标:主要结果测量指标:年龄特异性浸润性黑色素瘤发病率,以及年龄特异性黑色素瘤发病率的年均百分比变化(AAPC),按基于祖先的风险组别、性别和5岁年龄组划分:澳大利亚报告高风险(欧裔)血统的人口比例从 2006 年的 85.3% 下降到 2021 年的 71.1%。具有高风险血统的人的估计年龄标准化黑色素瘤发病率较高(2021 年:男性,每 100 000 人中有 82.2 [95% 置信区间 {CI},80.5-83.8] 例;女性,每 100 000 人中有 58.5 [95% 置信区间 {CI},57.8] 例)。5[95%置信区间,57.0-59.9]例)高于所有澳大利亚人(男性,67.8[95%置信区间,66.5-69.2]例/10万人口;女性,45.4[95%置信区间,44.3-46.5]例/10万人口)。总体而言,50 岁或以上的澳大利亚人以及具有高风险血统的澳大利亚人的 AAPCs 一直呈阳性,但只有 65 岁以上的某些年龄组的 AAPCs 才具有统计学意义。34岁或以下人群的AAPC呈阴性,但一般没有统计学意义:结论:在澳大利亚,黑色素瘤发病率在一些较年轻的年龄组中有所下降,包括在高风险血统人群中。同期的社会和行为变化导致紫外线辐射暴露水平降低,这可能是这些变化的原因之一。
{"title":"Changes in the incidence of melanoma in Australia, 2006–2021, by age group and ancestry: a modelling study","authors":"David C Whiteman,&nbsp;Rachel E Neale,&nbsp;Peter Baade,&nbsp;Catherine M Olsen,&nbsp;Nirmala Pandeya","doi":"10.5694/mja2.52404","DOIUrl":"10.5694/mja2.52404","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To estimate the incidence of melanoma in Australia among people with ancestries associated with low, moderate, or high risk of melanoma, by sex and 5-year age group; to establish whether age-specific incidence rates by ancestry risk group have changed over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study design</h3>\u0000 \u0000 <p>Modelling study; United States (SEER database) melanoma incidence rates for representative ancestral populations and Australian census data (2006, 2011, 2016, 2021) used to estimate Australian melanoma incidence rates by ancestry-based risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting, participants</h3>\u0000 \u0000 <p>Australia, 2006–2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main outcome measures</h3>\u0000 \u0000 <p>Age-specific invasive melanoma incidence rates, and average annual percentage change (AAPC) in age-specific melanoma rates, by ancestry-based risk group, sex, and 5-year age group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The proportion of people in Australia who reported high risk (European) ancestry declined from 85.3% in 2006 to 71.1% in 2021. The estimated age-standardised melanoma incidence rate was higher for people with high risk ancestry (2021: males, 82.2 [95% confidence interval {CI}, 80.5–83.8] cases per 100 000 population; females, 58.5 [95% CI, 57.0–59.9] cases per 100 000 population) than for all Australians (males, 67.8 [95% CI, 66.5–69.2] cases per 100 000 population; females, 45.4 [95% CI, 44.3–46.5] cases per 100 000 population). AAPCs were consistently positive for Australians aged 50 years or older, both overall and for people with high risk ancestry, but were statistically significant only for some age groups beyond 65 years. AAPCs were negative for people aged 34 years or younger, but were generally not statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Melanoma incidence has declined in some younger age groups in Australia, including among people with high risk ancestry. Social and behavioural changes over the same period that lead to lower levels of ultraviolet radiation exposure probably contributed to these changes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 5","pages":"251-257"},"PeriodicalIF":6.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52404","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The rise and rise of predatory journals and the risks to clinical practice, health and careers: the APAME 2024 Sydney declaration on predatory or pseudo journals and publishers 掠夺性期刊的兴起和崛起,以及对临床实践、健康和职业生涯的风险:APAME 2024 悉尼掠夺性或伪期刊和出版商宣言。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-01 DOI: 10.5694/mja2.52410
Nicholas J Talley, Virginia Barbour, José Florencio F Lapeña, Peter L Munk, Wilfred C G Peh
<p>On 28–30 August 2024, the annual meeting of the Asia Pacific Association of Medical Journal Editors (APAME) was held at the University of Newcastle, New South Wales. APAME is a non-governmental, non-partisan, non-profit organisation that supports and promotes medical journalism in the Asia–Pacific region. It provides a forum for education and exchange of ideas and interacts with numerous organisations around the world, including the World Health Organization, to fulfill its mission. This year, APAME issued the <i>Sydney declaration on predatory or pseudo journals and publishers</i> (Box). “Predatory journals” can be defined as those “which actively solicit manuscripts and charge publications fees without providing robust peer review and editorial services”.<span><sup>1</sup></span> However, there is a continuum from predatory to low quality publishing behaviour and even reputable journals are not immune to providing low quality services on occasion.</p><p>Over the last quarter century, medical journals have undergone significant change in how they are published, and virtually all academic journals are now wholly or predominantly available online. Most new journals are fully online. At the same time, there has been a move towards open access publishing to make medical knowledge more globally accessible, thus reducing inequity in knowledge access. Open access has become mandated by many grant-funding organisations and embraced by many researchers. Open access requires a shift of financial model from consumers — largely institutions paying for access to academic journals — to the authors or their institutions paying for work to be universally available to all readers. Although there is a diverse variety of open access models, including access through university repositories and consortial support for open access journals, one model, in which open access is paid for at the level of individual articles, can be particularly problematic. Not only can this model lead to inequity in ability to pay (ie, if authors are not affiliated with institutions that can support open access), it also opens the door to predatory publishing practices.<span><sup>2, 3</sup></span></p><p>Although most traditional journals that adopted open access have maintained their high standards of peer review and adherence to ethical codes of practice, thousands of fraudulent journals have arisen with the explicit goal of enticing unsuspecting authors to pay to get their articles published. Unfortunately, these journals have also tapped into a key driver of academic success — publish or perish. Where authors are driven by incentives to publish many articles, and especially where speed of publishing can be very important and authors are unaware of the predatory practices, they may see these journals as a convenient option, and, ironically, cost effective, as they usually have lower article processing charges than reputable journals.<span><sup>1</sup></span></p><p>Authors are typical
此外,越来越多的掠夺性期刊研究成果被引用到知名期刊上的文章中,这表明劣质甚至虚假研究的污染正在蔓延。7、8 更为复杂的是,发表在劣质期刊上的好文章可能永远不会被人看到,因为这些期刊中的许多都没有被公认的知名索引(如PubMed、开放存取期刊目录、Web of Science、Scopus)收录,也可能不会永久存档。最重要的是,他们可能得不到任何反馈来改进自己的文章(这是健康的同行评审过程的一部分)。4 作者的资金也被骗走,这尤其令人痛心,因为许多向这些期刊投稿的作者来自中低收入国家。最后,如果作者在简历中列出这些文章,他们未来的教育和就业机会就有可能减少。使用人工智能程序检测掠夺性期刊的效果至今不佳。10 有掠夺性期刊的名单,但可能不完整、不可靠、过时11 。12 读者在评估自己阅读的研究成果时也必须小心谨慎。APAME 发表这份声明,是因为人们越来越关注掠夺性期刊造成的损害。13 APAME 与其他类似组织一起,不仅致力于避免掠夺性期刊的做法,而且尽一切努力教育编辑、同行评审员、作者、图书馆员和合乎道德的出版商,并增强他们的能力,以尽量减少其影响。尼古拉斯-塔利是APAME主席、MJA名誉主编、UptoDate栏目编辑、Mayo Clinic Proceedings副主编、《胃肠病学》编辑顾问委员会主席。尼古拉斯-塔利从 Allakos(胃十二指肠嗜酸性粒细胞疾病;2021 年)、twoXAR Viscera Labs(肠易激综合征-腹泻;美国,2021 年)、IsoThrive(食道微生物组;2021 年)、BluMaiden(微生物组顾问委员会;2021 年)、Rose Pharma(肠易激综合征;2021 年)、Intrinsic Medicine(人乳低聚糖;2022 年)、Comvita Mānuka Honey(消化健康;2021 年)、Astra Zeneca(2022 年)、布朗大学(纤维与通便系统综述;2024-2025 年)。此外,尼古拉斯-塔利还拥有 1998 年 Nepean 消化不良指数(NDI)专利、梅奥/塔利授权的专利许可问卷 Talley 肠道疾病问卷、"功能性胃肠道疾病诊断标志物 "澳大利亚临时专利申请 2021901692、"治疗与菌群失调相关的老年神经退行性疾病的方法和组合物 "美国申请 No.Virginia Barbour 是《MJA》杂志的主编,该杂志是 Wiley-CAUL 协议的一部分,因开放存取出版而收取费用。她是DORA(研究评估宣言)的联合主席,也是NHMRC研究质量指导委员会的成员。Jose Lapeña是APAME的前任主席、世界医学编辑协会(WAME)的秘书和开放存取期刊目录的WAME董事会代表,也是《菲律宾耳鼻咽喉头颈外科杂志》的主编。Peter Munk曾任《加拿大放射医师协会杂志》主编、《英国放射学杂志》副主编和APAME国际联络员。Wilfred Peh曾任APAME主席、《新加坡医学杂志》顾问和前任主编、《英国放射学杂志》高级编辑。
{"title":"The rise and rise of predatory journals and the risks to clinical practice, health and careers: the APAME 2024 Sydney declaration on predatory or pseudo journals and publishers","authors":"Nicholas J Talley,&nbsp;Virginia Barbour,&nbsp;José Florencio F Lapeña,&nbsp;Peter L Munk,&nbsp;Wilfred C G Peh","doi":"10.5694/mja2.52410","DOIUrl":"10.5694/mja2.52410","url":null,"abstract":"&lt;p&gt;On 28–30 August 2024, the annual meeting of the Asia Pacific Association of Medical Journal Editors (APAME) was held at the University of Newcastle, New South Wales. APAME is a non-governmental, non-partisan, non-profit organisation that supports and promotes medical journalism in the Asia–Pacific region. It provides a forum for education and exchange of ideas and interacts with numerous organisations around the world, including the World Health Organization, to fulfill its mission. This year, APAME issued the &lt;i&gt;Sydney declaration on predatory or pseudo journals and publishers&lt;/i&gt; (Box). “Predatory journals” can be defined as those “which actively solicit manuscripts and charge publications fees without providing robust peer review and editorial services”.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; However, there is a continuum from predatory to low quality publishing behaviour and even reputable journals are not immune to providing low quality services on occasion.&lt;/p&gt;&lt;p&gt;Over the last quarter century, medical journals have undergone significant change in how they are published, and virtually all academic journals are now wholly or predominantly available online. Most new journals are fully online. At the same time, there has been a move towards open access publishing to make medical knowledge more globally accessible, thus reducing inequity in knowledge access. Open access has become mandated by many grant-funding organisations and embraced by many researchers. Open access requires a shift of financial model from consumers — largely institutions paying for access to academic journals — to the authors or their institutions paying for work to be universally available to all readers. Although there is a diverse variety of open access models, including access through university repositories and consortial support for open access journals, one model, in which open access is paid for at the level of individual articles, can be particularly problematic. Not only can this model lead to inequity in ability to pay (ie, if authors are not affiliated with institutions that can support open access), it also opens the door to predatory publishing practices.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Although most traditional journals that adopted open access have maintained their high standards of peer review and adherence to ethical codes of practice, thousands of fraudulent journals have arisen with the explicit goal of enticing unsuspecting authors to pay to get their articles published. Unfortunately, these journals have also tapped into a key driver of academic success — publish or perish. Where authors are driven by incentives to publish many articles, and especially where speed of publishing can be very important and authors are unaware of the predatory practices, they may see these journals as a convenient option, and, ironically, cost effective, as they usually have lower article processing charges than reputable journals.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Authors are typical","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 5","pages":"248-250"},"PeriodicalIF":6.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52410","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leave no-one behind: reducing health disparities for women experiencing homelessness in Australia 不让一个人掉队:减少澳大利亚无家可归妇女的健康差距。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-30 DOI: 10.5694/mja2.52430
Lisa J Wood, Rhiannon C Villiers
<p>Homelessness in Australia has increased substantially in the past decade, with women constituting 44.1% of the 122 494 people recorded as homeless in 2021.<span><sup>1</sup></span> Of these women, 50.7% are Aboriginal and Torres Strait Islander and 37.8% are aged 55 years and older.<span><sup>1</sup></span> Moreover, these census statistics are conservative: 381 168 people sought assistance from specialist homelessness services across Australia in 2022–23, with female participants making up almost two-thirds (62.9%).<span><sup>2</sup></span></p><p>Homelessness includes visible rough sleeping (eg, in streets, parks, cars), couch surfing and accommodation in refuges, crisis and transitional accommodation and dwellings below minimum community standards. In a “cycle of perpetual vulnerability”,<span><sup>3</sup></span> women who are homeless are at a high risk of violence, sexual assault, exploitation and theft, and trauma is cumulative and compounded. These vulnerabilities, along with other social determinants of health relating to housing and material circumstances, lead to negative health impacts, as well as affecting engagement with the health system.<span><sup>4</sup></span></p><p>Within the health care system, prevention, early identification and intervention are key to positive individual outcomes,<span><sup>5</sup></span> including for people experiencing or at risk of experiencing homelessness.<span><sup>6</sup></span> Family and domestic violence is the most common driver of homelessness in Australia, accounting for 45% of homelessness service requests for assistance in 2022–23.<span><sup>2</sup></span> Older women experiencing relationship breakdowns or financial insecurity are also acutely vulnerable.<span><sup>7</sup></span> The dearth of affordable housing and rentals, compounded by the cost of living crisis, has seen homelessness and emergency relief services nationwide reporting unprecedented requests for help, including from women and families.<span><sup>8</sup></span></p><p>Importantly, health sector workers should be mindful that people may not disclose their homelessness to health or other government services, and that the nomenclature of “no fixed address” under-reports homelessness. Fear of stigma and judgement, shame, or the requirement to provide a postal address to access services are among common reasons for not disclosing homelessness.<span><sup>9</sup></span> Women who are pregnant or who have children face additional barriers, as homelessness can be a red flag for child protection intervention or removal.<span><sup>10</sup></span></p><p>Homelessness is linked to significantly higher rates of both physical and mental health conditions irrespective of sex, including preventable chronic diseases.<span><sup>11</sup></span> Multimorbidity is common,<span><sup>11</sup></span> but significant barriers hinder health care access, engagement, primary care and prevention (Box 1).<span><sup>12</sup></span> Trauma underlies many of
此外,鉴于土著妇女和托雷斯海峡岛民妇女无家可归的比例过高,并认识到世代相传的无家可归现象和殖 民化的持续影响,文化安全和创伤知情护理至关重要,这一点尤为重要。对于致力于提供公平护理的医疗服务机构而言,原住民控制组织和原住民医疗工作者的参与以及对其专业知识的认可至关重要。然而,根据我们在这一弱势群体身边工作的综合经验,要想共同减少她们所面临的巨大健康障碍和差异,就必须认识到她们的韧性,并以同情和不带评判的态度倾听她们的心声,这一点无论怎样强调都不为过。澳大利亚圣母大学通过澳大利亚大学图书馆员理事会促成了 Wiley - 澳大利亚圣母大学协议的一部分--开放存取出版。
{"title":"Leave no-one behind: reducing health disparities for women experiencing homelessness in Australia","authors":"Lisa J Wood,&nbsp;Rhiannon C Villiers","doi":"10.5694/mja2.52430","DOIUrl":"10.5694/mja2.52430","url":null,"abstract":"&lt;p&gt;Homelessness in Australia has increased substantially in the past decade, with women constituting 44.1% of the 122 494 people recorded as homeless in 2021.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Of these women, 50.7% are Aboriginal and Torres Strait Islander and 37.8% are aged 55 years and older.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Moreover, these census statistics are conservative: 381 168 people sought assistance from specialist homelessness services across Australia in 2022–23, with female participants making up almost two-thirds (62.9%).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Homelessness includes visible rough sleeping (eg, in streets, parks, cars), couch surfing and accommodation in refuges, crisis and transitional accommodation and dwellings below minimum community standards. In a “cycle of perpetual vulnerability”,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; women who are homeless are at a high risk of violence, sexual assault, exploitation and theft, and trauma is cumulative and compounded. These vulnerabilities, along with other social determinants of health relating to housing and material circumstances, lead to negative health impacts, as well as affecting engagement with the health system.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Within the health care system, prevention, early identification and intervention are key to positive individual outcomes,&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; including for people experiencing or at risk of experiencing homelessness.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; Family and domestic violence is the most common driver of homelessness in Australia, accounting for 45% of homelessness service requests for assistance in 2022–23.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Older women experiencing relationship breakdowns or financial insecurity are also acutely vulnerable.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; The dearth of affordable housing and rentals, compounded by the cost of living crisis, has seen homelessness and emergency relief services nationwide reporting unprecedented requests for help, including from women and families.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Importantly, health sector workers should be mindful that people may not disclose their homelessness to health or other government services, and that the nomenclature of “no fixed address” under-reports homelessness. Fear of stigma and judgement, shame, or the requirement to provide a postal address to access services are among common reasons for not disclosing homelessness.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; Women who are pregnant or who have children face additional barriers, as homelessness can be a red flag for child protection intervention or removal.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Homelessness is linked to significantly higher rates of both physical and mental health conditions irrespective of sex, including preventable chronic diseases.&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt; Multimorbidity is common,&lt;span&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/span&gt; but significant barriers hinder health care access, engagement, primary care and prevention (Box 1).&lt;span&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/span&gt; Trauma underlies many of","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 7","pages":"354-356"},"PeriodicalIF":6.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-index hospital re-admissions after hospitalisation with acute myocardial infarction and geographic remoteness, New South Wales, 2005–2020: a retrospective cohort study 2005-2020 年新南威尔士州急性心肌梗死住院后的非指数再入院率与地理偏远程度:一项回顾性队列研究。
IF 6.7 2区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-08-28 DOI: 10.5694/mja2.52420
Md Shajedur Rahman Shawon, Jennifer Yu, Art Sedrakyan, Sze-Yuan Ooi, Louisa Jorm
<div> <section> <h3> Objectives</h3> <p>To examine the frequency of re-admissions to non-index hospitals (hospitals other than the initial discharging hospital) within 30 days of admission with acute myocardial infarction in New South Wales; to examine the relationship between non-index hospital re-admissions and 30-day mortality.</p> </section> <section> <h3> Study design</h3> <p>Retrospective cohort study; analysis of hospital admissions (Admitted Patient Data Collection) and mortality data (Registry of Births, Deaths and Marriages).</p> </section> <section> <h3> Setting, participants</h3> <p>Adults admitted to NSW hospitals with acute myocardial infarction re-admitted to any hospital within 30 days of discharge from the initial hospitalisation, 1 January 2005 – 31 December 2020.</p> </section> <section> <h3> Main outcome measures</h3> <p>Proportion of re-admissions within 30 days of discharge to non-index hospitals, and associations of non-index hospital re-admissions with demographic and initial hospitalisation characteristics and with 30-day and 12-month mortality, each by residential remoteness category.</p> </section> <section> <h3> Results</h3> <p>Of 168 097 people with acute myocardial infarction discharged alive, 28 309 (16.8%) were re-admitted to hospital within 30 days of discharge, including 11 986 to non-index hospitals (42.3%); the proportion was larger for people from regional or remote areas (50.1%) than for people from major cities (38.3%). The odds of non-index hospital re-admission were higher for people with ST-elevation myocardial infarction, for people whose index admissions were to private hospitals, who were transferred between hospitals or had undergone revascularisation during the initial admission, were under 65 years of age, or had private health insurance; the influence of these factors was generally larger for people from regional or remote areas than for those from large cities. After adjustment for potential confounders, non-index hospital re-admission did not influence mortality among people from major cities (30-day: adjusted odds ratio [aOR], 1.09; 95% confidence interval [CI], 0.99–1.20; 12-month: aOR, 0.98, 95% CI, 0.93–1.03), but was associated with reduced mortality for people from regional or remote areas (30-day: aOR, 0.81; 95% CI, 0.70–0.95; 12-month: aOR, 0.88; 95% CI, 0.81–0.96).</p> </section> <section> <h3> Conclusions</h3>
研究目的研究新南威尔士州急性心肌梗死患者入院后 30 天内再次入住非指标医院(非最初出院医院)的频率;研究非指标医院再次入院与 30 天死亡率之间的关系:回顾性队列研究;分析入院数据(入院患者数据收集)和死亡率数据(出生、死亡和婚姻登记):2005年1月1日至2020年12月31日期间,新南威尔士州医院收治的急性心肌梗死患者在首次住院出院后30天内再次入住任何医院:出院后30天内再次入住非指标医院的比例,以及非指标医院再次入院与人口统计学特征和首次住院特征以及30天和12个月死亡率之间的关系,按居住地偏远程度分类:在 168 097 名活着出院的急性心肌梗死患者中,有 28 309 人(16.8%)在出院后 30 天内再次入院,其中有 11 986 人(42.3%)再次入住非指标医院;来自地区或偏远地区的患者(50.1%)再次入院的比例高于来自大城市的患者(38.3%)。ST段抬高型心肌梗死患者、入院指数为私立医院的患者、转院患者或在首次入院时接受过血管重建术的患者、65岁以下的患者或拥有私人医疗保险的患者再次入院的几率更高;这些因素对地区或偏远地区患者的影响通常大于大城市患者。在对潜在的混杂因素进行调整后,非指数再入院并不影响大城市人群的死亡率(30 天:调整后的几率比 [aOR],1.09;95% 置信区间 [CI],0.99-1.20;12 个月:aOR,1.09;95% 置信区间 [CI],0.99-1.20)。20;12 个月:aOR,0.98,95% CI,0.93-1.03),但与地区或偏远地区居民的死亡率降低有关(30 天:aOR,0.81;95% CI,0.70-0.95;12 个月:aOR,0.88;95% CI,0.81-0.96):澳大利亚人口地域分散,专科服务由公立和私立医院共同提供,这意味着急性心肌梗死患者在最初转入专科医院后,再次入住非指标医院是不可避免的。对于来自地区或偏远地区的患者来说,再次入住非指标医院与较好的死亡率结果相关。
{"title":"Non-index hospital re-admissions after hospitalisation with acute myocardial infarction and geographic remoteness, New South Wales, 2005–2020: a retrospective cohort study","authors":"Md Shajedur Rahman Shawon,&nbsp;Jennifer Yu,&nbsp;Art Sedrakyan,&nbsp;Sze-Yuan Ooi,&nbsp;Louisa Jorm","doi":"10.5694/mja2.52420","DOIUrl":"10.5694/mja2.52420","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objectives&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To examine the frequency of re-admissions to non-index hospitals (hospitals other than the initial discharging hospital) within 30 days of admission with acute myocardial infarction in New South Wales; to examine the relationship between non-index hospital re-admissions and 30-day mortality.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Retrospective cohort study; analysis of hospital admissions (Admitted Patient Data Collection) and mortality data (Registry of Births, Deaths and Marriages).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting, participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Adults admitted to NSW hospitals with acute myocardial infarction re-admitted to any hospital within 30 days of discharge from the initial hospitalisation, 1 January 2005 – 31 December 2020.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main outcome measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Proportion of re-admissions within 30 days of discharge to non-index hospitals, and associations of non-index hospital re-admissions with demographic and initial hospitalisation characteristics and with 30-day and 12-month mortality, each by residential remoteness category.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Of 168 097 people with acute myocardial infarction discharged alive, 28 309 (16.8%) were re-admitted to hospital within 30 days of discharge, including 11 986 to non-index hospitals (42.3%); the proportion was larger for people from regional or remote areas (50.1%) than for people from major cities (38.3%). The odds of non-index hospital re-admission were higher for people with ST-elevation myocardial infarction, for people whose index admissions were to private hospitals, who were transferred between hospitals or had undergone revascularisation during the initial admission, were under 65 years of age, or had private health insurance; the influence of these factors was generally larger for people from regional or remote areas than for those from large cities. After adjustment for potential confounders, non-index hospital re-admission did not influence mortality among people from major cities (30-day: adjusted odds ratio [aOR], 1.09; 95% confidence interval [CI], 0.99–1.20; 12-month: aOR, 0.98, 95% CI, 0.93–1.03), but was associated with reduced mortality for people from regional or remote areas (30-day: aOR, 0.81; 95% CI, 0.70–0.95; 12-month: aOR, 0.88; 95% CI, 0.81–0.96).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 ","PeriodicalId":18214,"journal":{"name":"Medical Journal of Australia","volume":"221 6","pages":"310-316"},"PeriodicalIF":6.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.5694/mja2.52420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medical Journal of Australia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1